Cottage Street Advisors LLC Sells 1,266 Shares of Bristol-Myers Squibb Co (BMY)

Cottage Street Advisors LLC decreased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 8.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,924 shares of the biopharmaceutical company’s stock after selling 1,266 shares during the quarter. Cottage Street Advisors LLC’s holdings in Bristol-Myers Squibb were worth $854,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Blue Chip Partners Inc. grew its position in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its position in Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 15 shares during the last quarter. Chilton Investment Co. LLC grew its position in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 26 shares in the last quarter. Keel Point LLC grew its position in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 39 shares in the last quarter. Finally, Hudock Capital Group LLC grew its position in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 69.56% of the company’s stock.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $65.35 on Thursday. The stock has a market cap of $106,960.00, a price-to-earnings ratio of 110.76, a price-to-earnings-growth ratio of 1.96 and a beta of 1.08. Bristol-Myers Squibb Co has a 52 week low of $51.56 and a 52 week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the business posted $0.63 EPS. equities research analysts expect that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were paid a dividend of $0.40 per share. The ex-dividend date was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.45%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Several equities analysts have weighed in on the stock. Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price objective on the stock in a research report on Thursday, February 1st. BMO Capital Markets set a $51.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Wednesday. Leerink Swann lifted their price objective on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research report on Tuesday, February 6th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Credit Suisse Group set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $65.58.

COPYRIGHT VIOLATION WARNING: “Cottage Street Advisors LLC Sells 1,266 Shares of Bristol-Myers Squibb Co (BMY)” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://weekherald.com/2018/02/15/cottage-street-advisors-llc-sells-1266-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply